Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qilisheng + Ablation for Unresectable Breast Cancer
NCT03240224Phase 3Completed
- Sponsor
- Fuda Cancer Hospital
- Start
- Sep 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Life information rehabilitation therapy in breast cancer (4 arms), sponsored by Fuda Cancer Hospital. Primary endpoint: Relief degree of tumors at 3 months. Started Sep 2017; status: completed.
02
Drugs
Life information rehabilitation therapy
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03240224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03240224.